Worsening in oxygen saturation and exercise capacity predict adverse outcome in patients with Eisenmenger syndrome

详细信息    查看全文

• 作者：Alex ; er Van De Bruaene ; Pieter De Meester ; Jens-Uwe Voigt ; Marion Delcroix ; Agnes Pasquet ; Julie De Backer ; Michel De Pauw ; Robert Naeije ; Jean-Luc Vachi¨¦ry ; Bernard P. Paelinck ; Marielle Morissens ; Werner Budts
• 关键词：Eisenmenger syndrome ; Pulmonary hypertension ; Oxygen saturation ; Exercise capacity ; Outcome
• 刊名：International Journal of Cardiology
• 出版年：2013
• 出版时间：30 September, 2013
• 年：2013
• 卷：168
• 期：2
• 页码：1386-1392
• 全文大小：549 K

文摘

Objectives

To evaluate (1) changes in clinical, biochemical and echocardiographic parameters, (2) whether deterioration in exercise capacity and resting oxygen saturation (SatO2-rest) are related with adverse outcome and (3) its additional value in predicting outcome in Eisenmenger patients.

Methods

Seventy-seven (36 ¡À 14 years, 30 % male) patients were included and prospectively followed. Changes between baseline and final visit were evaluated. Clinical deterioration was defined as a deterioration in exercise capacity or SatO2-rest. Univariate and multivariate analyses were performed to evaluate predictors of outcome defined as the need for hospitalization due to right heart failure, transplantation, or all-cause mortality. Finally, the additional prognostic value of deterioration in exercise capacity and SatO2-rest was evaluated.

Results

During a mean follow-up period of 4.0 ¡À 2.1 years, 27 (35 % ) events occurred. Patients in the event-group presented with an deterioration in NYHA class (P < 0.0001), 6 minute walk distance (P = 0.006) and SatO2-rest (P < 0.0001). After adjustment for baseline variables, multivariate Cox regression analysis indicated that clinical deterioration was independently associated with adverse outcome.

Conclusions

Clinical deterioration, defined as a deterioration in exercise capacity or SatO2-rest was associated with adverse outcome in Eisenmenger patients. Moreover, these parameters provided additional information on which patients would develop an event and may benefit from initiation or escalation of disease targeting therapy.